Solutions for your clinical trial as Britain leaves the EU
Sharp can deliver a robust and flexible solution for your clinical trial today and post-Brexit, offered through the following capabilities:
- Existing clinical and commercial facilities in the U.K. and the E.U (The Netherlands)
- Both facilities offer Qualified Person and related services
- Established QP-to-QP agreements between the U.K. and The Netherlands
- Our proven logistics partnership will avoid transport and import-related delays
- Importation experience and expertise from the U.S. to the U.K. and the E.U.
- Offering the benefit of a reverse VAT charge mechanism (Art 23) in The Netherlands
Sharp Netherlands facility approved for clinical operations
Sharp has received regulatory licensing and approvals to support clinical activities from its facility in The Netherlands.
The IMP and WDA licences mean Sharp can manufacture and distribute IMPs to clinical sites across the continent from a European site. Read more here.
Video: A commentary on the impact of Brexit
Eulned Morgan, Welsh Minister for International Relations and Ian Morgan, General Manager of Sharp Clinical UK comment on the on-going impact of Brexit for BBC Wales.